<unk>  is a combination of<unk>  and ivacaftor that is FDA approved for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to<unk> /ivacaftor based on in vitro data and/or clinical evidence.   Common adverse reactions include headache, nausea, sinus congestion, and dizziness.
Tezacaftor / ivacaftor
Lumacaftor and ivacaftor
Fluticasone/salmeterol
Ivacaftor
Arformoterol tartrate
Diflorasone
Azelastine Hydrochloride
Desoximetasone